Insmed, Inc. (NASDAQ:INSM) Receives $175.53 Consensus PT from Analysts

Shares of Insmed, Inc. (NASDAQ:INSM) have been given an average recommendation of “Moderate Buy” by the twenty-one ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nineteen have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $175.5294.

Several brokerages recently issued reports on INSM. TD Cowen lifted their price target on shares of Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a report on Thursday, November 20th. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 20th. William Blair initiated coverage on Insmed in a research note on Wednesday, August 20th. They issued an “outperform” rating for the company. Mizuho set a $196.00 price objective on Insmed in a research report on Wednesday, October 29th. Finally, The Goldman Sachs Group increased their target price on Insmed from $196.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, October 31st.

Insmed Stock Up 0.9%

NASDAQ INSM opened at $206.43 on Friday. The business has a fifty day moving average price of $173.90 and a two-hundred day moving average price of $130.53. The stock has a market capitalization of $44.02 billion, a PE ratio of -36.15 and a beta of 1.05. Insmed has a fifty-two week low of $60.40 and a fifty-two week high of $209.77. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed’s quarterly revenue was up 52.4% on a year-over-year basis. During the same period last year, the firm posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. Equities analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, Director Leo Lee sold 75,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $195.90, for a total value of $14,692,500.00. Following the completion of the sale, the director directly owned 54,677 shares in the company, valued at $10,711,224.30. This represents a 57.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of Insmed stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total value of $5,820,000.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at $7,073,434. The trade was a 45.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 257,922 shares of company stock worth $44,556,283 over the last quarter. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

Several institutional investors and hedge funds have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC grew its holdings in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Insmed during the 3rd quarter valued at approximately $523,000. Danske Bank A S bought a new position in shares of Insmed during the 3rd quarter valued at approximately $346,000. NewEdge Advisors LLC purchased a new position in shares of Insmed in the third quarter valued at $452,000. Finally, Castleark Management LLC increased its position in Insmed by 82.5% in the third quarter. Castleark Management LLC now owns 5,730 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 2,590 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.